Showing 3381-3390 of 5773 results for "".
- Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Diseasehttps://modernod.com/news/kiora-pharmaceuticals-receives-12-million-in-research-tax-credits-to-advance-the-treatment-of-ophthalmic-disease/2481713/Kiora Pharmaceuticals announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to research tax incentives from the Austrian and Australian governments for research expenditures performed in 2021 and 2022. The funds were received as part of government incentiv
- SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and Other Chronic Ophthalmic Diseaseshttps://modernod.com/news/spyglass-pharma-completes-90-million-series-c-financing-to-advance-novel-treatments-for-glaucoma-and-other-chronic-ophthalmic-diseases/2481711/SpyGlass Pharma announced the closing of $90 million in Series C financing to enable the company to conduct multiple US clinical trials of SpyGlass’ drug delivery platform. The SpyGlass system has the potential to deliver multiple years of medical therapy to address significant unmet n
- Bausch + Lomb Acquires Blink OTC Eye Drops from J&J Visionhttps://modernod.com/news/bausch-lomb-acquires-blink-eye-drops-from-jj-vision/2481709/The latest in a string of major moves by Bausch + Lomb, the company announced it is purchasing the Blink product line of eye and contact lens
- Bausch + Lomb to Acquire Xiidra from Novartishttps://modernod.com/news/bausch-lomb-will-acquire-xiidra/2481704/Bausch + Lomb announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5%. Xiidra is a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DE
- Elios Vision Completes Enrollment in US Pivotal Trial; Expands US Pre-Launch Teamhttps://modernod.com/news/elios-vision-completes-enrollment-in-us-pivotal-trial-expands-us-pre-launch-team-and-continues-to-generate-commercial-uptake-in-europe/2481701/Elios Vision announced it has completed enrollment for its pivotal trial of more than 300 patients with mild to moderate glaucoma treated with the Elios procedure in combination with cataract surgery. Elios is an implant-free procedure that uses excimer laser technology for the treatmen
- Ciliatech Presents 2-Year Postoperative Results on New Cilio-Scleral Surgical Approach for Treating Glaucomahttps://modernod.com/news/ciliatech-presents-2-year-postoperative-results-on-new-cilio-scleral-surgical-approach-for-treating-glaucoma/2481698/Ciliatech announced it will present the preliminary results of the second 2-year postoperative clinical trial (SAFARI II) on its Cilia-scleral Interposition Device (CID) during the World Glaucoma Congress, taking place this week. Ciliatech will present results showing sta
- SriniVas R. Sadda, MD, Named 2023-2024 ARVO President Electhttps://modernod.com/news/srinivas-r-sadda-md-named-2023-2024-arvo-president-elect/2481697/Doheny Eye Institute announced that SriniVas R. Sadda, MD, was named President Elect of the Association for Research in Vision and Ophthalmology (ARVO) during its 2023 annual meeting in New Orleans. Dr. Sadda has been a member of ARVO for a number of years, and s
- Luminopia Raises Money to Support Full Commercial Rollout of Amblyopia Therapeutichttps://modernod.com/news/luminopia-raises-money-to-support-full-commercial-rollout-of-amblyopia-therapeutic/2481692/Luminopia announced it has raised an additional $16 million in new capital to support the full commercial rollout later this year of the company’s lead product, Luminopia, a software-based therapeutic for amblyopia, the leading cause of vision loss among children. Luminopia w
- Bruder Healthcare Expands Dry Eye Portfolio with Eye Care Distribution of AllerFocus Percutaneous Allergy Testhttps://modernod.com/news/bruder-healthcare-expands-dry-eye-portfolio-with-eye-care-distribution-of-allerfocus-percutaneous-allergy-test/2481689/Bruder Healthcare announced an eye care industry distribution agreement with Tallahassee, Florida-based AllerFocus for its Percutaneous Allergy Test, a needle-free allergy screening for 78 of the most common airborne and environmental allergens. Financial terms of the deal w
- iSTAR Medical to Present New 3-Year STAR-GLOBAL Data at World Glaucoma Congresshttps://modernod.com/news/istar-medical-to-present-new-3-year-star-global-data-at-world-glaucoma-congress/2481683/iSTAR Medical announced that it will be hosting a symposium where it will present 3-year interim data from the STAR-GLOBAL trial and will also be running a dry lab at its booth at the 10th World Glaucoma Congress (WGC) taking place in Rome, Italy from June 28 to July 1, 2023.